TheraVitae CEO to Present Adult Blood-borne Stem Cells at BioThailand 2005

Share Article

Dr. Valentin Fulga, CEO of TheraVitae, Ltd., the producer of VesCell™, adult stem cell therapy for heart disease was an invited lecturer at a special forum on regenerative medicine at BioThailand 2005, a biannual international biotechnology conference that is being held November 2-5, at The Queen Sirikit National Convention Center in Bangkok.

Dr. Valentin Fulga, CEO of TheraVitae, Ltd., the producer of VesCell™, adult stem cell therapy for heart disease was an invited lecturer at a special forum on regenerative medicine at BioThailand 2005, a biannual international biotechnology conference that is being held November 2-5, at The Queen Sirikit National Convention Center in Bangkok.

The aim of this special forum, sponsored by Thailand Center of Excellence for Life Sciences (TCELS), was to provide opportunities for discussion on new developments and future trends in the area of regenerative medicine as well as issues related to the technology of stem cell therapy.

Dr. Fulga’s lecture, “Adult Blood-borne Stem Cells – a Powerful Therapeutic Tool” presented the scientific background of blood-borne stem cells and the concepts that led to the development of VesCell, TheraVitae's commercial adult stem cell product used for treating certain types of heart disease. Additionally, Dr. Fulga presented experimental data showing the various effects of the cells and the rationale behind using them in clinical practice.

Dr. Fulga described the event as, "a wonderful opportunity for lecturers from leading US, European and Asian institutions to discuss hot topics, exchange ideas and gain a better understanding of the scientific, legal and ethical aspects of autologous adult stem cell treatments.

Two hospitals in Thailand, Chaophya Hospital and Bangkok Heart Hospital, are currently using VesCell to treat no-option patients suffering form coronary artery disease and heart failure. TheraVitae recently announced plans to initiate clinical trials for peripheral vascular disease, a disorder common in diabetic patients leading to severe limb sores and pain.

About VesCell

VesCell consists of a patient's own adult stem cells harvested from approximately ½ pint of the patient's own blood and is used to treat heart disorders. Once harvested, the cells are differentiated and expanded in vitro at the TheraVitae laboratories in Israel and are ready for implantation in about one week. The cellular product is a viable alternative for patients who either cannot undergo or choose not to undergo the standard revascularization treatments such as Coronary Artery Bypass Grafting (CABG).

For more information about VesCell, please visit http://www.vescell.com

About TheraVitae

TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, and Hong Kong.

For more information about TheraVitae, please visit http://www.theravitae.com

About BioThailand 2005

BioThailand 2005 an international biotechnology event held every two years in the beautiful and vibrant city of Bangkok, Thailand. BioThailand 2005 caters to conference participants in the field of biotechnology, pharmaceutical, health and environment, agricultural, education, and financial sector.

For more information about BioThailand 2005, please visit http://biothailand.biotec.or.th

TheraVitae, Ltd.

36/72 PS Tower, 21/Fl.,

Sukhumvit 21, Klongtoey Nua,

Bangkok 10110

Thailand

Tel: 662-664-4290

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay D. Lenner Jr.
Visit website